QUANTEL Medical Signs Global Licensing Agreement with IRIDEX
CHICAGO, November 9, 2012 /PRNewswire/ –
QUANTEL Medical today announced that IRIDEX and QUANTEL Medical have signed a global
patent licensing agreement that gives QUANTEL access to IRIDEX MicroPulse technology. This
proprietary technology provides ophthalmologists a noninvasive treatment for
sight-threatening diseases of the eye, including complications associated with diabetes.
Unlike conventional laser therapy, MicroPulse spares the eye tissue responsible for vision
while producing comparable clinical effect to traditional methods that destroy tissue.
“There is a significant need in the market place for efficient and durable therapies
for retinal diseases associated with the growth of diabetes and the aging population,”
stated Will Moore, IRIDEX President and CEO. He continued, “With 10-year follow up data, a
growing global user base, and significant patent protection, MicroPulse is emerging as a
future standard of care.” The license agreement will allow QUANTEL to market and display
IRIDEX’ MicroPulse technology for their range of high quality clinical lasers and is the
next step in gaining broad market availability of MicroPulse photocoagulation lasers. Both
QUANTEL and IRIDEX offer a full line of laser systems that offer standard photocoagulation
in addition to MicroPulse laser therapy.
Moore continued, “Further establishing the MicroPulse brand and technology as an
IRIDEX property is critical as the market continues to recognize its broad applicability
for retina and other procedures. We look forward to working with others in the industry as
it migrates toward a new standard for laser therapy in additional segments.”
“The global clinical evidence supporting IRIDEX’ MicroPulse laser technology was an
important factor in this decision”, stated Mr. Jean-Marc Gendre, CEO of QUANTEL Medical.
He continued, “By aligning our market strategies with another industry leader, we believe
the ophthalmic community will have greater access to MicroPulse technology, helping to
improve the standard of care for retinal diseases. We also believe that this collaboration
will be the most efficient method to standardize MicroPulse clinical protocols for our
About MicroPulse Technology
MicroPulse is a Fovea-friendly tissue-sparing laser delivery therapy that works by
electronically “chopping” the laser emission into trains of microsecond pulses. This
enhances the physician’s ability to more precisely control the laser effects on target
tissues, offering the potential for ocular treatment with less collateral effects than
conventional laser treatments.
IRIDEX Corporation was founded in 1989 and is a worldwide leader in developing,
manufacturing, and marketing innovative and versatile laser-based medical systems,
delivery devices and consumable instrumentation for the ophthalmology market. We maintain
a deep commitment to the success of our customers, with comprehensive technical, clinical,
and service support programs. IRIDEX is dedicated to a standard of excellence, offering
superior technology for superior results. IRIDEX products are sold in the United States
through a direct sales force and internationally through a combination of a direct sales
force and a network of approximately 70 independent distributors into over 100 countries.
For further information, visit the IRIDEX’ website at http://www.iridex.com.
About QUANTEL Medical
Founded in 1993 and headquartered in Clermont-Ferrand, France, QUANTEL Medical is a
global ophthalmic medical device company dedicated to developing leading technologies to
improve the treatment of ocular diseases. QUANTEL Medical has a strong emphasis in
research and development, resulting in many first-to-market product introductions, and a
comprehensive product portfolio of diagnostic ultrasound and surgical lasers for
ophthalmologists. The products are available through direct sales operations in the U.S.
and France, and through independent distributors in over 80 countries.
QUANTEL Medical is a division of Quantel (QUA:EN), a world-wide leader in the
development of solid-state lasers for scientific and industrial applications.
CONTACT: Levi Hall, Marketing Director, Medical, Quantel USA, email@example.com
SOURCE QUANTEL Medical